Compare ENSC & CTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENSC | CTM |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 93.0M |
| IPO Year | N/A | N/A |
| Metric | ENSC | CTM |
|---|---|---|
| Price | $1.43 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 417.4K | ★ 1.7M |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,487,973.00 | ★ $50,606,863.00 |
| Revenue This Year | N/A | $23.00 |
| Revenue Next Year | N/A | $11.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.51 | ★ 11.09 |
| 52 Week Low | $1.26 | $0.26 |
| 52 Week High | $10.96 | $2.83 |
| Indicator | ENSC | CTM |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 50.44 |
| Support Level | $1.26 | $1.00 |
| Resistance Level | $1.69 | $1.24 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 27.97 | 41.67 |
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.